

Total No. of Questions :6]

SEAT No. :

**P1467**

**[5049]-706**

[Total No. of Pages :2

**F.Y. B. Pharmacy**

**4.7.6. BIOPHARMACEUTICS AND PHARMACOKINETICS  
(2013 Pattern) (Semester - VII)**

*Time : 3 Hours]*

*[Max. Marks :70*

*Instructions to the candidates:*

- 1) All questions are compulsory.*
- 2) Answers to the two sections should be written in separate answer books.*
- 3) Neat labelled diagrams must be drawn wherever necessary.*
- 4) Figures to the right indicate full marks.*

**SECTION-I**

**Q1)** Explain mechanisms involved in absorption of drug from GI tract. **[10]**

OR

Define apparent volume of distribution. Discuss factors affecting apparent volume of distribution.

**Q2)** Answer the following (Any 5): **[15]**

- a) Effect of surface area of drug on drug dissolution and absorption.
- b) Absorption of drug after buccal administration.
- c) Drug-food interaction.
- d) Phase I reactions in biotransformation of drugs.
- e) Pulmonary route of administration.
- f) BCS class I drugs.
- g) Discuss in brief physiological barriers to drug distribution.

**P.T.O.**

**Q3)** Write short note on (Any 2): **[10]**

- a) Effect of dosage form on absorption after oral administration.
- b) Clearance concept and renal clearance.
- c) Non-Linear pharmacokinetics.
- d) Necessity of In-vitro-In-vivo co-relation.

**SECTION-II**

**Q4)** Define Bioavailability and Bioequivalence and explain study designs for conducting bioequivalence study. **[10]**

OR

Explain ONE Compartmental open model for assessment of parameters by IV Bolus administration.

**Q5)** Answer the following (Any 5): **[15]**

- a) Discuss factors affecting bioavailability of drugs.
- b) What are the advantages of urinary data over plasma data.
- c) How bioavailability determined on the basis of urinary excretion data.
- d) What is Wash out period.
- e) What is Two compartmental analysis.
- f) What is significance of compartmental analysis.
- g) Define and explain in short  $C_{max}$  and  $t_{max}$ .

**Q6)** Write short note on (Any 2): **[10]**

- a) Method of residual.
- b) Biowaivers.
- c) Assessment of Bioavailability.
- d) Single verses Multiple dose study.

*EEE*